Immunization to protect against diphtheria, pertussis (whooping cough), and tetanus is jointly known as DPT vaccine. DPT immunizations are given in a series of 5 shots at 2, 4, 6, 18 months of age and 4-6 years of age. Thanks to vaccination programs, these diseases have become less common. Though, there are still unvaccinated persons capable of carrying and passing diphtheria and pertussis to others who are not vaccinated. Tetanus bacteria are prevalent in natural surroundings, such as contaminated soil.
Globally the market for DPT vaccine is increasing rapidly. The major factor that derives the growth of DPT vaccine is the increasing deaths in children due to pertussis. Furthermore increasing awareness for DPT vaccines is increasing the growth of DPT vaccine market. Factors such as high birth rate, demand in number of geriatric population, government initiatives, growth in adoption of DPT vaccination, and government insurance and reimbursement scenario are projected to drive the DPT vaccine market globally.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1357 .
Diphtheria is a respiratory disease which causes breathing problems, paralysis, heart failure, and death. It’s highly transmittable and is spread easily by coughing and sneezing.
Tetanus, is caused by a bacteria often found in soil. Once it enters the body it releases a toxin that attacks the nervous system, causing muscle spasms and finally death.
Pertussis, also extremely contagious, causes coughing spasms so severe that it makes difficult for children to eat, drink even breathe. It can lead to pneumonia, seizures, brain damage, and death.
These three diseases are highly dangerous for a child if not treated properly. This awareness has led the maximum growth of DPT vaccine to protect an infant from these life risky diseases.
On the other hand, factors such as vaccine injuries and opposing event are expected to hinder the growth of the pertussis vaccine market globally.
Global DPT vaccine Market-Competitive Analysis:
Sanofi Pasteur, the vaccines division of Sanofi announced on March 2015 that the U.S. Food and Drug Administration (FDA) has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. The FDA approval of Quadracel vaccine provides health care providers with a new mixture vaccine, potentially decreasing the number of vaccine injections children aged 4 through 6 would need.
Major players in this market are: Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India) and many others.
Browse Complete Report at https://www.marketresearchfuture.com/reports/dpt-vaccine-market-1357 .
Global DPT vaccine Market-Segmentation:
Global DPT vaccine market is segmented into 3 divisions:
Segmentation by Type: DPaT, DTwP, Tdap.
Segmentation by Application: Diphtheria, pertussis, tetanus and others.
Segmentation by Region: North America, Europe and Asia Pacific.
Global DPT vaccine Market- Regional Analysis:
Majorly North America is dominating huge part of the market. US, Canada and Mexico are highly contributing in the market growth. Europe is in the second place with countries like UK, Germany some of the major contributor in the global DPT vaccine market. Asia Pacific has countries like China, Japan and India where the population rate is really high. These high population is driving the market growth of DPT vaccine.
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –